null

Bevacizumab Biosimilar (Anti-VEGFA) Antibody (HDBS0059)

SKU:
HDBS0059
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Angiogenesis
Disease Area:
Cancer
Disease Area:
Ocular Disorders
Protein:
VEGFA
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
$479

Description

system_update_altDatasheet

Bevacizumab (Anti-VEGFA) Biosimilar Antibody (HDBS0059)

The Anti-VEGFA Bevacizu Biosimilar (HDBS0059) is a highly specific and reliable monoclonal antibody designed for research involving Vascular Endothelial Growth Factor A (VEGFA), a key player in angiogenesis and tumor growth. This biosimilar antibody, derived from Bevacizumab, is produced using advanced technology to ensure high affinity and specificity for VEGFA.The Anti-VEGFA Bevacizu Biosimilar (HDBS0059) is validated for use in various applications, including ELISA, immunohistochemistry, and flow cytometry, making it versatile for different research needs. It specifically targets VEGFA, enabling precise detection and analysis in cancer cells and tissues, making it an essential tool for studies in oncology and angiogenesis.

Given the vital role of VEGFA in promoting tumor angiogenesis and progression, understanding its mechanisms and regulation is crucial for developing targeted therapies in cancer treatment. The Anti-VEGFA Bevacizu Biosimilar (HDBS0059) provides researchers with a valuable tool to further explore the relationship between VEGFA and tumor development, ultimately leading to potential breakthroughs in cancer therapy.